Altimmune (ALT) News Today

Altimmune, Inc. (NASDAQ: ALT) saw its stock hold near recent lows as investors weighed positive regulatory and analyst developments against a barrage of securities class-action notices from multiple law firms. Below is a summary of the key headlines moving the stock today:

• Positive Sentiment: US FDA grants fast track designation to Altimmune’s pemvidutide for alcohol use disorderUS FDA grants fast track designation to Altimmune’s pemvidutide to treat alcohol use disorder
• Positive Sentiment: Seven analysts assign Altimmune an average “Moderate Buy” rating, reflecting cautious optimism on pipeline progressAltimmune, Inc. (NASDAQ:ALT) Given Average Recommendation of "Moderate Buy" by Analysts
• Negative Sentiment: Rosen Law Firm urges investors who bought ALT between August 10, 2023 and June 25, 2025 to secure counsel before the October 6, 2025 lead plaintiff deadlineROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action
• Negative Sentiment: Pomerantz LLP reminds investors with losses in ALT shares to contact counsel regarding newly filed securities class actionINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines
• Negative Sentiment: Levi & Korsinsky notifies ALT investors of class action and October 6, 2025 deadline for lead plaintiff applicationsOctober 6, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ALT
• Negative Sentiment: Rosen Law Firm issues similar GlobeNewswire notice urging ALT holders to secure counsel before the October deadlineROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action
• Negative Sentiment: The Gross Law Firm reminds shareholders of ALT of a pending securities suit and October 6 deadline to discuss rightsAltimmune, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before October 6, 2025 to Discuss Your Rights
• Negative Sentiment: Pomerantz repeats its GlobeNewswire alert on the class action suit and upcoming deadlines for ALT investorsINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines
• Negative Sentiment: Berger Montague notifies purchasers of ALT securities of class action and the October deadline for lead plaintiff motionsINVESTOR REMINDER: Berger Montague Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Deadline
• Negative Sentiment: Faruqi & Faruqi investigates claims on behalf of ALT investors with losses exceeding $75,000 and highlights October 6 deadlineSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
• Negative Sentiment: The Gross Law Firm issues a second PR notice urging shareholders to contact counsel before the October 6, 2025 class action deadlineContact The Gross Law Firm by October 6, 2025 Deadline to Join Class Action Against Altimmune, Inc.(ALT)